tbuckley/cabot-search huggingface dataset:
SAT0093 Association of Formal Education Level (EDUC) with Clinical Status in Korean Fibromyalgia (FM) Patients: Table 1.
Authors: S.-H. Park, I. Castrejόn, J.-Y. Choe, S.-K. Kim, H.-J. Lee, T. Pincus
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Low formal education level (EDUC), an indicator of socioeconomic status, is an established risk factor to develop rheumatoid arthritis (RA) as well as many other diseases,<sup>1</sup> and low EDUC is associated with poor clinical status in RA according to patient questionnaires, joint counts and laboratory tests.<sup>2</sup> Formal studies of possible associations of EDUC with more severe status in FM have not been reported. The diagnosis of FM depends primarily on a patient history of extensive pain and other symptoms, so clinical status might be best addressed by patient-reported outcomes (PROs) on self-report questionnaires. <h3>Objectives</h3> To investigate possible associations of EDUC, as well as age, duration of disease (DUR) and body mass index (BMI), with PRO scores in Korean patients with FM. <h3>Methods</h3> Responses of Korean patients with FM on the widespread pain index (WPI), symptom severity scale (SS), fibromyalgia impact questionnaire (FIQ), and multidimensional health assessment questionnaire/routine assessment of patient index data (MDHAQ/RAPID3) were analyzed. Statistical significance was tested using Spearman correlations of PROS with EDUC, age, DUR and BMI. A series of multivariate regressions was computed for each PRO as a dependent variable, and for age, DUR, BMI and EDUC as independent variables. <h3>Results</h3> In univariate correlations (data not shown) EDUC was correlated significantly with WPI (rho=-0.41, p=0.01), SS (rho=-0.47, p&lt;0.01), FIQ-symptoms (rho=-0.39, p&lt;0.02), FIQ-total score (rho=-0.35, p=0.03) and MDHAQ pain (rho=-0.33, p=0.04), generally at higher levels than age, DUR or BMI with these variables. Age also was correlated significantly with FIQ-overall impact, FIQ-symptoms, FIQ-total score, MDHAQ-PATGL and RAPID3; DUR also was correlated significantly with FIQ-overall impact, FIQ-symptoms and FIQ-total score (data not shown). No significant correlations were seen with BMI. In multivariate regressions (Table), EDUC was significantly and independently associated with SS, FIQ-symptoms, FIQ-total score, MDHAQ pain, RAPID3. Age also was significant in regressions, generally at lower beta coefficients than EDUC; DUR and BMI were not significant (Table 1). <h3>Conclusions</h3> In patients with FM, many PROs are associated significantly with EDUC, generally at higher levels than with age, DUR or BMI. EDUC should be included in all studies of patients with FM, as well as other rheumatic diseases. <h3>References</h3> J Chronic Dis 1987;40:865-74. Arthritis Rheum 1988;31:1346-57. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3920
Unconscious goals: Specific or unspecific? The potential harm of the goal/gene analogy
Authors: Bence Nanay
Journal: Behavioral and Brain Sciences (2014)

Abstract Huang &amp; Bargh's (H&amp;B's) definition of goals is ambiguous between “specific goals” – the end-state of a token action I am about to perform – and “unspecific goals” – the end-state of an action-type (without specifying how this would be achieved). The analogy with selfish genes pushes the authors towards the former interpretation, but the latter would provide a more robust theoretical framework.
The Role of Research in the Modern Voluntary Teaching Hospital
Authors: Owen H. Wangensteen
Journal: New England Journal of Medicine (1952)

AN ADDITION to a voluntary hospital in which a university has an important stake is an event that merits the commendation of all who have a serious interest in medical education. This is an occasion that definitely suggests a reciprocal interest of the community in the university and of the university in the community. There is adequate precedent in this country for this type of relation between institutions of learning and hospitals. Moreover, the more completely the two groups can fuse their responsibilities into a common effort, the better. It is significant that Harvard University, one of the great universities . . .
Case 40-1974
Authors: Richard C. Cabot, Robert E. Scully, Betty U. McNeely, Robert W. Carey, Sanford I. Roth
Journal: New England Journal of Medicine (1974)

Presentation of CaseA 68-year-old man was admitted to the hospital because of lethargy.Sixteen years previously he was seen at this hospital because of a left ureteral calculus. Thereafter, he was lost to follow-up examination. In the interval diabetes mellitus and angina pectoris developed; he gained considerable weight and smoked heavily. Two months before entry he was referred to this hospital because of an abdominal aortic aneurysm. He was advised to lose weight and to discontinue smoking and was requested to return in three months for consideration of elective resection of the aneurysm. Eight days before admission he entered . . .
Deep Venous Thrombosis in the Leg Following Effort or Strain
Authors: Chilton Crane
Journal: New England Journal of Medicine (1952)

SO-CALLED "effort thrombosis" of the axillary or subclavian vein has been the subject of at least 70 communications in the literature since 1930; upwards of 300 cases have been reported.1 2 3 4 5 6 7 8 Deep venous thrombosis of the lower extremity secondary to fracture, joint injury or external trauma represents an all too familiar entity. Indeed, Vance9 was able to report a series of 34 autopsied cases of fatal pulmonary embolism following fractures of the lower extremity, and Martland10 reported 55 autopsied cases of fatal pulmonary embolism following various leg injuries. Bauer11 has pointed out that venous thrombosis is 12 times more common in . . .
FRI0115 Non-steroidal anti-inflammatory drug use and the risk of cardiovascular disease in patients with rheumatoid arthritis – is there a risk?:
Authors: J. Lindhardsen, O. Ahlehoff, G.H. Gislason, O.R. Madsen, S. Jacobsen, C. Torp-Pedersen, P.R. Hansen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Safety data from clinical trials have raised concerns over the cardiovascular (CV) safety of non-steroidal anti-inflammatory drug (NSAID) use in general. Despite the widespread use of NSAIDs in RA patients, the few reports available from RA populations have not indicated an increased CV risk associated with commonly used NSAIDs. This suggests that the benefits of NSAID use (eg. improved mobility and pain relief) to some extent may balance the adverse CV effects observed in non-RA individuals. <h3>Objectives</h3> To evaluate the CV risk associated with use of several NSAIDs in RA patients and controls. <h3>Methods</h3> The study was designed as a register-based, longitudinal, nationwide cohort study in the period 1997 to 2009. Data were gathered from in- and out-hospital records (diagnoses), pharmacy records (prescriptions) and several civil registers (vital status, emigration and annual income). RA patients were identified by the combination of RA diagnoses and DMARD treatment and matched with 4 randomly selected controls based on age and sex. Individuals with prior myocardial infarction (MI) and stroke were excluded. Overall NSAID exposure and exposure to distinct NSAIDs were determined from redeemed prescriptions. Outcome of interest was the combined endpoint of myocardial infarction, stroke and/or CV mortality (primary cause of death). Risk was assessed by fitting Cox regression models stratified by RA status. <h3>Results</h3> 17 320 RA patients were included (71% females, mean age 59 years) and 69 280 matched control. 6 284 events occurred during follow-up (801 during NSAID use). RA patients were exposed to NSAID in 25% of follow-up compared to 5% in the control group. The overall risk associated with NSAID use was significantly lower in RA patients than in controls (hazard ratio 1.21 vs. 1.49, p&lt;0.001). This pattern was also generally present when examining the individual NSAIDs (see table for details), and the risk associated with overall NSAID use in RA patients seemed primarily driven by rofecoxib and diclofenac treatment with little or no risk associated with the other NSAIDs examined. At low and moderate daily dosages, most NSAIDs were associated with no or low risk of adverse CV event in RA patients. <h3>Conclusions</h3> This study found that NSAID use in RA patients is frequent and may be associated with an increased risk of CV disease. However, the magnitude of such risks is significantly lower than non-RA individuals and differed among NSAIDs. The results support a strongly individualised approach to NSAID treatment in RA patients based on the need for pain relief, the individual characteristics of the RA patient and the safety profile of the various NSAIDs available. <h3>Disclosure of Interest</h3> None Declared
Abstract 5398: Direct interaction of inhibitory molecules LAG-3 and PD-1 in murine CD8+ T cell signaling
Authors: Ruea-Yea Huang, Cheryl Eppolito, Junko Matsuzaki, Kunle Odunsi
Journal: Cancer Research (2012)

Abstract Chronic stimulation by tumor antigens results in exhaustion of antigen-specific T cells and loss of ability to produce key cytokines that are critical for the maintenance of T cell function. We have previously demonstrated that a subset of tumor antigen-specific CD8+ T cells coexpressing LAG-3 and PD-1 are impaired in IFN-γ and TNF-α production and that simultaneous blockade of LAG-3 and PD-1 restores effector function of ovarian tumor antigen-specific T cells in humans. Recently, others have reported that dual blocade of LAG-3 and PD-1 via either by antibodies or gene knockout leads to severe autoimmunity and enhanced immunity to tumors in mice. However, direct evidence of molecular interaction between LAG-3 and PD-1 in T cell signaling is lacking. The signaling molecules downstream of LAG3 are also unknown. Using a combination of ImageStream and confocal microscopy analyses, here we demonstrate that LAG-3 and PD-1 molecules co-localize in approximately 10-15% of activated murine antigen specific CD8+ T cells. Co-localization also occurred with trans-Golgi vesicles, microtubule organizing center, and early/recycling endosomes. Reciprocal immunoprecipitation with specific antibodies for LAG-3 and PD-1 revealed a physical association between LAG-3 and PD-1 and this interaction was abolished in T cells isolated from LAG3- and PD-1 knockout mice. The recruitment of Src family tyrosine kinases and phosphatases to the LAG-3 and PD-1 interaction complex are also implicated. Our data reveal a potential molecular mechanism by which LAG3 and PD-1 co-regulate T cell function. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5398. doi:1538-7445.AM2012-5398
THU0355 Monotherapy versus combination therapy in the treatment of fibromyalgia
Authors: S. Metyas, M. Ibrahim, E.C. Ortiz, S. Maher, D. Arkfeld
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> At the present time three drugs (pregabalin, duloxetine, milnacipran) are approved by the American Food and Drug Administration (FDA) for the treatment of fibromyalgia. There is no medication currently that is capable of complete symptom control, as the available drugs have been shown to improve only one or two fibromyalgia symptoms. <h3>Objectives</h3> The aim of the present study was to assess the potential additive or synergistic effects of combined pharmacotherapy in comparison to monotherapy in treatment of fibromyalgia. <h3>Methods</h3> This was a retrospective study reviewing 785 patients diagnosed with fibromyalgia. Pregabalin, flexibly dosed (50-450 mg/day), was administered to 122 fibromyalgia patients in combination with Duloxetine, also flexibly dosed (30-120 mg/day), or Milnacipran (25-200 mg/day). Three hundred and thirty-four patients were administered one of the three FDA approved drugs alone. Outcome measures included the Fibromyalgia Impact Questionnaire (FIQ), The Brief Pain Inventory (BPI) and the patients' Global Improvement scale (PGI). Emergent adverse reactions were also recorded. <h3>Results</h3> Treatment with pregabalin in combination with either duloxetine or milnacipran was superior to monotherapy in regards to improvements in fibromyalgia severity, sleep quality, depression and pain interference with daily activity. Combination therapy resulted in an improvement in the pain score of 29.3% when compared to that of monotherapy. <h3>Conclusions</h3> Treatment with combined pharmacotherapy significantly improved fibromyalgia severity and associated symptomatology. Combination therapy is synergistic in their effects and yields greater results in multiple symptom domains compared to that of monotherapy. Larger, prospective trials should be developed to test this conclusion and to assess safety and tolerability of combination therapy. <h3>Disclosure of Interest</h3> S. Metyas Consultant for: Pfizer Pharmaceuticals, M. Ibrahim: None Declared, E. Ortiz: None Declared, S. Maher: None Declared, D. Arkfeld Consultant for: Cypress Pharmaceuticals
Nonanesthesiologist-administered propofol sedation: from the exception to standard practice. Sedation and monitoring trends over 20 years
Authors: L. Heuss, F. Froehlich, C. Beglinger
Journal: Endoscopy (2012)

The practice of sedation, including monitoring practice for digestive endoscopy, continues to evolve throughout the world. In many countries, including Switzerland, there is a trend towards increased utilization of sedation during both routine and advanced endoscopic procedures. Sedation improves patient satisfaction with endoscopy and also improves the quality of the examination. In addition, a trend can be observed towards an increasing use of propofol as the preferred sedative drug. Here we review the latest published data from surveys describing sedation and monitoring practice in different countries and compare them with our own data from successive nationwide surveys among Swiss gastroenterologists over a period of 20 years. This development between these socioeconomically very similar Western industrialized countries, however, shows some unique and surprising differences. In Germany and Switzerland, propofol use has become increasingly widespread, in Switzerland even to the extent that during the last few years propofol has overtaken benzodiazepine sedation, with an absolute majority of Swiss gastroenterologists using it without the assistance of an anesthesiologist. In addition, the change in Switzerland reflects a successful generalization of nonanesthesiologist-administered propofol (NAAP) sedation from the hospital setting to private practice.
AB0714 Validity of a simplified enthesitis ultrasound score in the diagnosis of spondyloarthritis
Authors: A. Haddouche, S. Slimani, S. Bendali, K. Makhsoum, A. Benmebarek, A. Ladjouze-Rezig
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The <i>Madrid sonography enthesitis index</i> (MASEI) is a validated ultrasound score for the diagnosis of spondyloarthritis. It explores six entheses and thus requires about 20 minutes to be performed for each patient by a trained sonographist. <h3>Objectives</h3> The aim of this study was to determine the validity of a simplified ultrasound score, limited to the exploration of two calcaneal sites (plantar aponeurosis and Achilles tendon), on Algerian spondyloarthritis (SpA), which is known to be more severe than European and north American one. <h3>Methods</h3> A bi-center case-control study on SpA (Amor’s criteria) patients was performed. Plantar aponeurosis and Achilles tendons were evaluated ultrasonographically (tendon thickness, structure, calcifications, erosions, Doppler Signal and bursitis) according to the description given for the MASEI score. Demographic and clinical parameters as well as pelvic X-rays were noted. A ROC curve was constructed in order to determine the cut-off value associated with the best sensitivity/specificity. <h3>Results</h3> Twenty-one SpA patients (15 males) and 17 controls (12 men) were recruited. Mean BMI and age were similar in both groups. Mean disease duration was 8.7 ± 6.8 years. The mean simplified ultrasound score was 1.35 ± 1.46 in controls and 7.19 ± 3.44 in SpA patients (<i>p</i> &lt; 0.001). The area under the curve was highly significant (0.933; <i>p</i> &lt; 0.001) and by choosing a cut-off value of ≥ 4 for positivity, we’ve obtained a sensitivity of 85.7% and a specificity of 94.2%. Radiographic sacro-iliitis had a sensitivity of 85%. among the 3 SpA patients without sacro-iliitis, 2 had a positive ultrasound score. <h3>Conclusions</h3> This study shows that a simplified ultrasound score based only on the evaluation of calcaneal enthesitis is feasible for the diagnostis of SpA on Algerian patients, with a clear benefit on time gain (5 minutes vs 20 minutes for the MASEI). <h3>Disclosure of Interest</h3> None Declared
Abstract LB-112: SP1 suppression is associated with poor prognosis in intestinal-type gastric adenocarcinoma
Authors: HunSeok Lee, Özgür Cem Erkin, Ensel Oh, Mi Jeong Kwon, Young Kee Shin
Journal: Cancer Research (2011)

Abstract Specificity protein 1 (SP1) is a DNA-binding protein that activates and regulates the transcription of multiple genes. Since aberrant expression of SP1 was known to be related to cancer development and progression, we focused on SP1 expression in gastric cancer and its correlation with disease outcomes. We discovered a different relationship between SP1 expression and patient survival in intestinal and diffuse-type gastric cancer. In diffuse-type gastric cancer, patient survival decreased as SP1 expression increased (P &amp;lt; 0.05) in accordance with previously published papers, whereas the lack of SP1 expression in intestinal-type gastric cancer was correlated significantly with poor survival (P &amp;lt; 0.05). Multivariate analysis demonstrated that SP1 downregulation is an independent negative prognostic factor in intestinal-type gastric cancer. When SP1 downreguation was forced in high SP1 expressor intestinal-type gastric cell line MKN28 with siRNA, both migration and invasion was increased but cell proliferation was decreased. In accordance with these results, microarray data in siRNA-transfected MKN28 showed that genes inhibiting migration were downregulated and the expression of genes negatively facilitating proliferation was increased. Both migration and invasion, however, in low SP1 expressor intestinal-type gastric cell line AGS was decreased by SP1 induction. In contrast to intestinal-type, in diffuse-type gastric cell line SNU484, high SP1 expressor, both migration and invasion were decreased by siRNA. Contrary to previous studies, which did not reflect differences between the 2 histological types, our results showed that weak SP1 expression is involved in cancer progression and metastasis, and leads to poor prognosis in intestinal-type gastric adenocarcinoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-112. doi:10.1158/1538-7445.AM2011-LB-112
Abstract P2-09-10: Feasibility Assessment of Pharmacogenomic Predictors Developed from Breast Cancer Cell Lines To Predict Breast Cancer Patient Pathological Response in Neoadjuvant Chemotherapy
Authors: K Shen, S Rice, D Gingrich, D Wang, C Tian, Z Ding, S Brower, P Ervin, S Huang, M Gabrin, N. Song
Journal: Cancer Research (2010)

Abstract Background: Studies of developing pharmacogenomic predictors from cancer cell lines to predict cancer patient clinical response and outcome to chemotherapy have yielded both positive and negative results. The variability in these results may arise from the noise inherent of microarray technology as well as the small sample size of in cell line studies. Therefore, it is greatly needed to evaluate the feasibility of using cell lines to develop pharmacogenomic predictors of patient pathological response. Material and Methods: Thirty breast cancer cell lines were exposed to 10 concentrations of paclitaxel-5-fluorouracil-doxorubicin-cyclophosphamide (TFAC) to measure in vitro chemosensitivity. Two independent and publicly available microarray datasets (Hoeflich and Neve) on these breast cancer cell lines together with the chemosensitivity results were used to identify pharmacogenomic predictors from each dataset. Two independent clinical trials (Hess and Popovici) with publically available data, having 130 and 100 patients respectively, were used as test sets to validate the accuracy of the pharmacogenomic predictors. All patients received TFAC as neoadjuvant therapy and the gene expression profiles of patients were assessed before receiving chemotherapy treatment. The patient's pathological complete response (pCR) was determined after treatment to evaluate the chemotherapy efficacy. The pharmacogenomic predictors developed from each of the cell line studies were evaluated for their ability to predict patient pCR in each of the clinical trials using the supervised principle component regression method. Results: The pharmacogenomic predictors identified from the Hoeflich and Neve cell line data (training sets) predicted pCR of the patients in the two clinical trials (test sets) with 64%-68% accuracy, 70%-87% sensitivity, and 60%-67% specificity when 100 genes were selected as pharmacogenomic predictors (Table 1). Conclusions: The four independent prediction results generated in this study demonstrate the feasibility of using breast cancer cell lines to identify pharmacogenomic predictors of response to chemotherapy treatment for breast cancer patients. Future studies will examine the use of drug responses from primary cultures of patient tumors to develop pharmacogenomic predictors of breast cancer patient responses to chemotherapy treatment. Table 1. Prediction of breast cancer patients’ pCR by pharmacogenomic predictors derived from breast cancer cell lines. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-09-10.